Daily bars for up to one year, weekly bars for the 5-year view. Averages are 50/200 trading days (10/40 weeks on the 5-year view). Triangles mark past earnings reports, colored by that day’s move; ticks mark ex-dividend dates — hover either for the date. Volume is the shaded bars under the price; switch on RSI or MACD above for a full-history oscillator panel, not just today’s reading.
Reader sentiment, not investment advice. One vote per visitor; click again to change it.
GENB is priced at $13.91 right now, up 1.61% on the session. That puts its market value at $1.79B, 2863rd largest among the 3132 stocks we cover.
The stock's 52-week band runs $11.00 to $22.67, and the latest print sits 38.6% under the top end of it.
3 analysts follow the stock and the average call is "buy". The mean target, $26.00, sits 86.9% over where the stock trades.
This summary is put together from the numbers on the page and updates when they do. It describes the data; it is not a forecast or a recommendation.
Composite of 2 factors below, ranked against the 3132 U.S. stocks BeStock covers.
Trading closer to its 52-week high than most peers scores higher.
3 analysts, consensus Buy.
How this is scored: each factor above is a 0–100 percentile rank against every other stock BeStock covers (or, for Wall Street, against the five-point Strong Buy–Sell scale). The overall grade is the plain average of whichever factors apply to this stock — no factor is weighted more than another. That average maps to a letter: A ≥ 85, B ≥ 70, C ≥ 50, D ≥ 30, otherwise F. Recomputed from the data on this page as prices and filings update — it describes where a stock ranks today, not a forecast, and not a BeStock recommendation to buy or sell.
GENB is not currently one of the 10 holdings in BeStock Momentum, our rules-based momentum strategy.
Since 2021-01-04, the strategy has returned 389% (231.1% for the equal-weight average of BeStock’s coverage over the same stretch). Holdings can change any trading day, not just on a fixed schedule. Backtested performance, updated weekly — not a guarantee of future results, and not a BeStock recommendation.
What Wall Street analysts and Morningstar's fair-value model expect for the stock
Wall Street’s average 12-month target is $26.00, 86.9% above today’s price, with a consensus rating of Buy. Morningstar’s fair value model puts the stock at $23.88, so shares trade 41.8% below that estimate.
Figures are Wall Street analyst consensus and Morningstar’s independent fair-value model, sourced as noted above.
Price return over each window, from adjusted daily and weekly closes
| Indicator | Value | Signal |
|---|---|---|
| Price vs 20-day average | -11.4% | Bearish |
| Price vs 50-day average | -10.2% | Bearish |
| RSI (14) | 38.2 | Bearish |
| MACD (12,26,9) | -0.44 | Bearish |
| Bollinger band position | 10% | Bearish |
Standard indicator readings worked out from daily closes. They describe how the price has behaved, not where it is going.
Quote as of Oct 6, 2026 3:20 am ET. Prices can lag the live tape. This is background information, not a recommendation.
Ranks are among the 3,132 or so U.S.-listed stocks BeStock covers, recalculated whenever prices refresh. A tile is left out when the measure does not apply, such as yield for a stock that pays no dividend.
$13.91 is the latest print for GENB, a move of +1.61% against yesterday's close of $13.69. Today's low and high so far: $13.45 and $14.06.
Equity value comes to $1.79B at the current price. By that measure it is number 2863 of the 3132 names in our coverage.
The year's floor is $11.00 and the ceiling $22.67. Shares are 38.6% away from that ceiling.
Our data shows no dividend paid by Generate Biomedicines over the trailing twelve months.
Of 3 analysts, 100% say buy, 0% hold and 0% sell. Price targets average $26.00, with the most cautious at $22.00 and the most optimistic at $30.00.
BeStock publishes market data and analysis for information only. Nothing here is investment advice or a solicitation to buy or sell any security, and none of it is tailored to your financial situation, goals, or risk tolerance. Quotes may be delayed and figures can contain errors; check primary sources before you trade. How we source and calculate these pages.
No comments yet — be the first to weigh in on GENB.